News & Updates
Filter by Specialty:
Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
Initiation of venetoclax for acute myeloid leukaemia (AML) in the outpatient setting with a pharmacist-led interdisciplinary protocol is both feasible and safe, reports a study.
Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
24 Nov 2023Thromboembolism rate lower than expected in Chinese patients with pancreatic cancer
Chinese patients with pancreatic cancer have a lower incidence of thromboembolism compared with Western populations, and thromboembolism does not affect overall survival (OS), researchers from the Chinese University of Hong Kong (CUHK) have reported.
Thromboembolism rate lower than expected in Chinese patients with pancreatic cancer
22 Nov 2023Melanoma diagnoses in 2020 tend to have thicker, more advanced tumours
Diagnoses of invasive cutaneous melanoma in the year 2020 are characterized by thicker, more ulcerated, and more advanced tumours, a recent study has found. Of note, a 2020 diagnosis is not associated with survival.
Melanoma diagnoses in 2020 tend to have thicker, more advanced tumours
21 Nov 2023Physical activity aids in recovery of cardiopulmonary function after lung cancer surgery
Cardiopulmonary function (CPF) recovery failure at 6 months after lung cancer surgery appears to be driven by reductions in lung function and moderate-to-vigorous physical activity (MVPA) from baseline to 2 weeks, suggests a study. Baseline PA and dyspnoea are also associated with the inability to recover CPF.
Physical activity aids in recovery of cardiopulmonary function after lung cancer surgery
16 Nov 2023Topical diclofenac prevents HFS in capecitabine-treated cancer patients
Patients with breast or gastrointestinal (GI) cancer who are being treated with capecitabine monotherapy may benefit from using topical diclofenac gel to prevent or reduce the incidence of hand-foot syndrome (HFS), a common side effect of some chemotherapy drugs, reports a recent study presented at ESMO 2023.
Topical diclofenac prevents HFS in capecitabine-treated cancer patients
15 Nov 2023Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer
First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.